Recombinant Human SUMO1 Protein (His Tag) (Active)

Cat. No : CDRP-00616

size:

Target Information
Target Name	SUMO1
Synonyms	Small Ubiquitin-Related Modifier 1; SUMO-1; GAP-Modifying Protein 1; GMP1; SMT3 Homolog 3; Sentrin; Ubiquitin-Homology Domain Protein PIC1; Ubiquitin-Like Protein SMT3C; Smt3C; Ubiquitin-Like Protein; UBL1; SUMO1; SMT3C; SMT3H3; UBL1; DAP1; OFC10; SENP2; SMT3
UniProt ID	P23946
Accession	AAH66306.1

Product Details
Expression Host	E.coli
Species	Human
Tag	N-His
Molar Mass	12.4 kDa
Sequence	Lys 288-Ser 461

Background
Small ubiquitin-like modifier protein (SUMO) modification is a highly dynamic process, catalyzed by SUMO-specific activating (E1), conjugating (E2) and ligating (E3) enzymes, and reversed by a family of SUMO-specific proteases (SENPs). Small ubiquitin-like modifier 1 (SUMO1) is a member of the superfamily of ubiquitin-like proteins. Despite its structural similarity with ubiquitin, SUMO1 does not seem to play any role in protein degradation. SUMO1 plays an important role in modulation of NOX activity required for ROS generation. SUMO1 haploinsufficiency results in cleft lip and palate in animal models. SUMO1 gene variation in human non-syndromic cleft lip with or without cleft palate (NSCLP) development. SUMO-1 may be useful as a novel target for therapy in oral squamous cell carcinoma (SCC) as well as a clinical indicator for tumor recurrence together with Mdm2.

Background

Small ubiquitin-like modifier protein (SUMO) modification is a highly dynamic process, catalyzed by SUMO-specific activating (E1), conjugating (E2) and ligating (E3) enzymes, and reversed by a family of SUMO-specific proteases (SENPs). Small ubiquitin-like modifier 1 (SUMO1) is a member of the superfamily of ubiquitin-like proteins. Despite its structural similarity with ubiquitin, SUMO1 does not seem to play any role in protein degradation. SUMO1 plays an important role in modulation of NOX activity required for ROS generation. SUMO1 haploinsufficiency results in cleft lip and palate in animal models. SUMO1 gene variation in human non-syndromic cleft lip with or without cleft palate (NSCLP) development. SUMO-1 may be useful as a novel target for therapy in oral squamous cell carcinoma (SCC) as well as a clinical indicator for tumor recurrence together with Mdm2.

Properties
Purity	>95% as determined by reducing SDS-PAGE.
Formulation	Lyophilized from sterile 20 mM Tris, 500 mM NaCl, pH7.5
Reconstitution	Please refer to the printed manual for detailed information.
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80 °C. Reconstituted protein solution can be stored at 4-8 °C for 2-7 days. Aliquots of reconstituted samples are stable at < -20 °C for 3 months.

! For research use only. Not intended for any clinical use.